The global endometrial cancer market size was estimated to be USD 26.61 billion in 2023 and is estimated to reach USD 49.01 billion by 2034 with a CAGR of 5.71% during the forecast period 2024-2034. Rising prevalence of endometrial cancer, Growing awareness about endometrial cancer and available therapies, Advancements in diagnostics and treatment, Government initiatives and funding, and increasing Collaborations and Partnerships will drive the market growth.
Governments worldwide are noticing the growing burden of endometrial cancer and launching various initiatives to fund research and development of new diagnostics and treatment options. Furthermore, various government agencies and healthcare organizations are implementing awareness campaigns and screening programs to promote early detection, which will ultimately drive market growth. For instance, Elekta AB received FDA 510(k) clearance in February 2023 for its Elekta Versa HD linear accelerator with Agility Head for enhanced image-guided radiation therapy, which may improve treatment outcomes for patients with endometrial cancer.
By type of cancer, the endometrial carcinoma segment accounted for the highest revenue-grossing segment in the global endometrial cancer market in 2023 owing to the increasing prevalence of endometrial carcinoma, advancements in early detection technologies, and the development of targeted therapies. For instance, Eisai Co., Ltd. received FDA clearance in August 2023 for treating adult patients with advanced or recurrent endometrial cancer who had previously received hormone therapy and a platinum-based regimen. The medication is called Halaven (Eribulin mesylate). Additionally, the uterine sarcomas segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness, improved diagnostic capabilities, and ongoing research initiatives, leading to a better understanding of uterine sarcomas and an increased demand for advanced and tailored treatment solutions.
By type of treatment, the surgery segment accounted for the highest revenue-grossing segment in the global endometrial cancer market in 2023 owing to the prevalence of early-stage endometrial cancer cases, the effectiveness of surgical interventions in localized treatment, and the continuous advancements in surgical techniques. For instance, in October 2023, F. Hoffmann-La Roche Ltd. announced the start of patient registration in the Phase III KEYNOTE-979 clinical study of Tecentriq (atezolizumab) for endometrial cancer. Additionally, the targeted therapies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased understanding of molecular mechanisms in endometrial cancer, ongoing research in targeted drug development, and the demand for more precise and personalized treatment options, propelling rapid growth in the targeted therapies segment.
By diagnosis method, the biopsy segment accounted for the highest revenue-grossing segment in the global endometrial cancer market in 2023 owing to the critical role it plays in accurate diagnosis, treatment planning, and disease staging, alongside advancements in biopsy techniques and increasing emphasis on early detection, For instance, Karyopharm Therapeutics reported encouraging outcomes in November 2023 from the Phase II KEYNOTE-1001 trial, which assessed Selinexor plus pembrolizumab in patients with advanced or recurrent endometrial cancer, showing potential clinical activity. Additionally, the CT scans segment is predicted to grow at the fastest CAGR during the forecast period owing to the continuous technological advancements in imaging, improved resolution and accuracy of CT scans, and the growing importance of comprehensive diagnostic approaches.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global endometrial cancer market in 2023 owing to the central role they play in providing comprehensive cancer care, including diagnostics, surgery, and follow-up treatments, alongside the increasing prevalence of endometrial cancer cases and the concentration of specialized medical services in hospital and clinic settings. For instance, Siemens Healthineers unveiled the Ethos therapy system in September 2023. This next-generation radiotherapy platform delivers superior image guiding and precision treatment capabilities, which may help patients with endometrial cancer. Additionally, the ambulatory surgical center's segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for outpatient procedures, advancements in minimally invasive surgical techniques, and the increasing focus on cost-effective and convenient healthcare delivery, driving a substantial increase in the demand for services provided by ambulatory surgical centers in the management of endometrial cancer.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of endometrial cancer, increasing adoption of advanced treatment modalities, and robust research and development activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to growing awareness, improving healthcare infrastructure, a rise in endometrial cancer incidences, and ongoing attempts to improve early detection and treatment capacities. For instance, U.S.-based Karyopharm Therapeutics Inc. reported encouraging initial results from the Phase 3 study of Selinexor for endometrial cancer in February 2022. The safety and efficacy of selinexor as a first-line maintenance treatment for patients with advanced or recurrent endometrial cancer were assessed in this study.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Governments worldwide are noticing the growing burden of endometrial cancer and launching various initiatives to fund research and development of new diagnostics and treatment options. Furthermore, various government agencies and healthcare organizations are implementing awareness campaigns and screening programs to promote early detection, which will ultimately drive market growth. For instance, Elekta AB received FDA 510(k) clearance in February 2023 for its Elekta Versa HD linear accelerator with Agility Head for enhanced image-guided radiation therapy, which may improve treatment outcomes for patients with endometrial cancer.
By type of cancer, the endometrial carcinoma segment accounted for the highest revenue-grossing segment in the global endometrial cancer market in 2023 owing to the increasing prevalence of endometrial carcinoma, advancements in early detection technologies, and the development of targeted therapies. For instance, Eisai Co., Ltd. received FDA clearance in August 2023 for treating adult patients with advanced or recurrent endometrial cancer who had previously received hormone therapy and a platinum-based regimen. The medication is called Halaven (Eribulin mesylate). Additionally, the uterine sarcomas segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness, improved diagnostic capabilities, and ongoing research initiatives, leading to a better understanding of uterine sarcomas and an increased demand for advanced and tailored treatment solutions.
By type of treatment, the surgery segment accounted for the highest revenue-grossing segment in the global endometrial cancer market in 2023 owing to the prevalence of early-stage endometrial cancer cases, the effectiveness of surgical interventions in localized treatment, and the continuous advancements in surgical techniques. For instance, in October 2023, F. Hoffmann-La Roche Ltd. announced the start of patient registration in the Phase III KEYNOTE-979 clinical study of Tecentriq (atezolizumab) for endometrial cancer. Additionally, the targeted therapies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased understanding of molecular mechanisms in endometrial cancer, ongoing research in targeted drug development, and the demand for more precise and personalized treatment options, propelling rapid growth in the targeted therapies segment.
By diagnosis method, the biopsy segment accounted for the highest revenue-grossing segment in the global endometrial cancer market in 2023 owing to the critical role it plays in accurate diagnosis, treatment planning, and disease staging, alongside advancements in biopsy techniques and increasing emphasis on early detection, For instance, Karyopharm Therapeutics reported encouraging outcomes in November 2023 from the Phase II KEYNOTE-1001 trial, which assessed Selinexor plus pembrolizumab in patients with advanced or recurrent endometrial cancer, showing potential clinical activity. Additionally, the CT scans segment is predicted to grow at the fastest CAGR during the forecast period owing to the continuous technological advancements in imaging, improved resolution and accuracy of CT scans, and the growing importance of comprehensive diagnostic approaches.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global endometrial cancer market in 2023 owing to the central role they play in providing comprehensive cancer care, including diagnostics, surgery, and follow-up treatments, alongside the increasing prevalence of endometrial cancer cases and the concentration of specialized medical services in hospital and clinic settings. For instance, Siemens Healthineers unveiled the Ethos therapy system in September 2023. This next-generation radiotherapy platform delivers superior image guiding and precision treatment capabilities, which may help patients with endometrial cancer. Additionally, the ambulatory surgical center's segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for outpatient procedures, advancements in minimally invasive surgical techniques, and the increasing focus on cost-effective and convenient healthcare delivery, driving a substantial increase in the demand for services provided by ambulatory surgical centers in the management of endometrial cancer.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of endometrial cancer, increasing adoption of advanced treatment modalities, and robust research and development activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to growing awareness, improving healthcare infrastructure, a rise in endometrial cancer incidences, and ongoing attempts to improve early detection and treatment capacities. For instance, U.S.-based Karyopharm Therapeutics Inc. reported encouraging initial results from the Phase 3 study of Selinexor for endometrial cancer in February 2022. The safety and efficacy of selinexor as a first-line maintenance treatment for patients with advanced or recurrent endometrial cancer were assessed in this study.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type of Cancer, Type of Treatment, Diagnosis Method, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Endometrial Cancer Market Report 2023 - 2034
Endometrial Cancer Market Analysis & Forecast by Type of Cancer 2023 - 2034 (Revenue USD Bn)
- Endometrial Carcinoma
- Uterine Sarcomas
Endometrial Cancer Market Analysis & Forecast by Type of Treatment 2023 - 2034 (Revenue USD Bn)
- Surgery
- Radiation Therapy
- Chemotherapy
- Hormone Therapy
- Targeted Therapy
Endometrial Cancer Market Analysis & Forecast by Diagnosis Method 2023 - 2034 (Revenue USD Bn)
- Biopsy
- Pelvic ultrasound
- Hysteroscopy
- CT scan
Endometrial Cancer Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals and Clinics
- Cancer Research Institutes
- Ambulatory Surgical Centers
Endometrial Cancer Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Endometrial Cancer Market: Type of Cancer Estimates & Trend Analysis
8. Endometrial Cancer Market: Type of Treatment Estimates & Trend Analysis
9. Endometrial Cancer Market: Diagnosis Method Estimates & Trend Analysis
10. Endometrial Cancer Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Endometrial Cancer Market
13. Europe Endometrial Cancer Market
14. Asia Pacific Endometrial Cancer Market
15. Latin America Endometrial Cancer Market
16. MEA Endometrial Cancer Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Elekta AB
- Karyopharm Therapeutics
- Eisai Co. Ltd.
- GSK plc
- Siemens Healthineers (Varian Medical Systems Inc.)
- Amgen Inc.
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis International AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- Illumina Inc.
- Medtronic plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 26.61 Billion |
| Forecasted Market Value ( USD | $ 49.01 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
